Management of Liver Nodules

Diagnostic Approach

For any liver nodule detected on ultrasound, management depends primarily on nodule size and imaging characteristics, according to the European Association for the Study of the Liver 1, 2
Nodules <1 cm should be followed with ultrasound every 3-4 months during the first year, as recommended by the American Association for the Study of Liver Diseases 2, 3
Nodules 1-2 cm require multiphasic contrast-enhanced CT or MRI for characterization, as suggested by the European Association for the Study of the Liver 1, 4
Nodules >2 cm can be diagnosed as HCC based on typical features on one imaging technique, according to the European Association for the Study of the Liver 2, 5

Regenerative nodules typically appear small, well-defined, multiple, and peripheral, without the typical HCC enhancement pattern, as described by the European Association for the Study of the Liver 4, 6
Dysplastic nodules may show some enhancement but not the classic HCC pattern, according to the European Association for the Study of the Liver 4, 6

Biopsy is recommended when imaging is inconclusive or atypical, as suggested by the American Association for the Study of Liver Diseases 1, 3
Core needle biopsy is preferred over fine needle aspiration for accurate diagnosis, according to the American Association for the Study of Liver Diseases 3

For regenerative nodules, follow with ultrasound every 3-4 months for the first year, as recommended by the American Association for the Study of Liver Diseases 2, 7
For high-grade dysplastic nodules, consider early intervention due to high risk of malignant transformation, as suggested by the European Association for the Study of the Liver 3

Dysplastic nodules can be difficult to distinguish from early HCC even on biopsy, as noted by the European Association for the Study of the Liver 1
Immunohistochemical markers can improve diagnostic accuracy, according to the American Association for the Study of Liver Diseases 3, 7
A negative biopsy result does not rule out HCC if the nodule increases in size during follow-up, as warned by the European Association for the Study of the Liver 4
The risk of needle-tract tumor seeding following biopsy is approximately 0.9-2.7% per year, as reported by the European Association for the Study of the Liver 4

For atypical nodules in non-cirrhotic livers, always obtain pathological diagnosis, as recommended by the American Association for the Study of Liver Diseases 3
In patients with multiple nodules, focus surveillance on those with higher-risk features, according to the European Association for the Study of the Liver 1, 6
Consider hepatobiliary contrast agents for MRI to improve characterization of nodules, as suggested by the European Association for the Study of the Liver 4, 5